4DMedical Expands U.S. Presence with Olympus SeleCT™ Screening Launch

An update from 4DMedical Ltd ( (AU:4DX) ) is now available.

Olympus Corporation has launched a new campaign for SeleCT™ Screening in the United States, utilizing 4DMedical’s lung density analysis technology to identify candidates for the Olympus Spiration™ Valve System. This large-scale deployment of AI-based lung imaging marks a significant commercial expansion for 4DMedical, enhancing its clinical utility in early detection and therapy enablement. The partnership addresses the underdiagnosis of COPD, particularly emphysema, and expands 4DMedical’s presence in interventional respiratory care, offering substantial commercial growth opportunities.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited is a global medical technology company at the forefront of respiratory care innovation. Utilizing advanced imaging and AI-powered solutions, the company provides unprecedented insights into lung function, facilitating earlier and more accurate diagnoses of respiratory diseases. Their patented XV Technology® allows for dynamic quantification of ventilation throughout the lungs, supporting physicians in detecting and monitoring airflow abnormalities with high sensitivity. 4DMedical integrates its solutions into existing hospital infrastructure through a Software as a Service (SaaS) model, enhancing routine imaging capabilities. The company further expanded its leadership in medical imaging with the acquisition of Imbio, an AI solutions pioneer for chronic lung and cardiothoracic diseases.

Average Trading Volume: 886,054

Technical Sentiment Signal: Sell

Current Market Cap: A$139.7M

For an in-depth examination of 4DX stock, go to TipRanks’ Stock Analysis page.